Cardlytics Seeks Shareholder Approval for Reverse Stock Split to Address Sub-$1.00 Price

summarizeSummary

Cardlytics, Inc. filed definitive additional proxy materials for its upcoming annual meeting, seeking shareholder approval for a reverse stock split and a reduction in authorized shares, likely to address its sub-$1.00 stock price and maintain listing.

check_boxKey Events · Corporate Governance and Compliance · CDLX

• Annual Meeting Scheduled

  Shareholders will vote on key proposals at the Annual Meeting on May 20, 2026.

• Reverse Stock Split Proposed

  The company is seeking approval for a reverse stock split, a common measure to raise the per-share price and potentially maintain stock exchange listing requirements.

• Authorized Shares Reduction

  Shareholders will also vote on a proposal to reduce the number of authorized shares, often accompanying a reverse split to manage potential dilution.

• Context of Financial Distress

  This proposal follows a challenging 2025, marked by a 16% revenue decline and a significant goodwill impairment, highlighting the company's need to address its stock price and financial stability.

auto_awesomeAnalysis · CDLX · Technology

The proposal for a reverse stock split is a significant development for Cardlytics, especially given its current stock price of $0.9821 and recent financial challenges, including a 16% revenue decline and a $49.1 million goodwill impairment in 2025. This move is typically undertaken by companies to increase their share price to meet minimum listing requirements, such as NASDAQ's $1.00 bid price rule, and avoid potential delisting. While a reverse split can temporarily boost the share price, it does not address the underlying operational or financial issues. The market often views such proposals negatively, as they can signal distress and may not prevent further stock price erosion in the long term. Investors should monitor the outcome of the shareholder vote and the company's subsequent performance.